研究发现,25%的医疗保险痴呆症患者仍然在没有明确理由的情况下获得高风险脑药物。 25% of Medicare dementia patients still get high-risk brain drugs with no clear reason, study finds.

尽管存在已知的风险,但根据2013年至2021年对美援署索赔的研究,美国约25%患有痴呆症的医疗保险受益人继续接受抗精神病和苯并二氮杂卓等高危中枢神经系统药物的处方。 Despite known risks, about 25% of Medicare beneficiaries with dementia in the U.S. continue to be prescribed high-risk central nervous system medications like antipsychotics and benzodiazepines, according to a study of Medicare claims from 2013 to 2021. 虽然这些药物的总体开药率略有下降,但三分之二以上的痴呆患者接受这些药物时没有文件证明临床理由。 While overall prescribing rates for these drugs declined slightly, over two-thirds of dementia patients receiving them had no documented clinical justification. 有认知障碍但无痴呆症的老年人的处方率也很高。 Older adults with cognitive impairment but no dementia also had high prescription rates. 研究人员强调,需要改进处方做法和更安全的替代品。 Researchers stress the need for improved prescribing practices and safer alternatives.